Log in to save to my catalogue

Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelin...

Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelin...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2678421893

Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelination in people with multiple sclerosis

About this item

Full title

Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelination in people with multiple sclerosis

Publisher

England: BMJ Publishing Group Ltd

Journal title

Journal of neurology, neurosurgery and psychiatry, 2022-09, Vol.93 (9), p.972-977

Language

English

Formats

Publication information

Publisher

England: BMJ Publishing Group Ltd

More information

Scope and Contents

Contents

BackgroundChronic demyelination is a major contributor to axonal vulnerability in multiple sclerosis (MS). Therefore, remyelination could provide a potent neuroprotective strategy. The ReBUILD trial was the first study showing evidence for successful remyelination following treatment with clemastine in people with MS (pwMS) with no evidence of dise...

Alternative Titles

Full title

Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelination in people with multiple sclerosis

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2678421893

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2678421893

Other Identifiers

ISSN

0022-3050

E-ISSN

1468-330X

DOI

10.1136/jnnp-2022-329221

How to access this item